Iqymune

Human Normal Immunoglobulin, the active ingredient in Iqymune, is an immunoglobulin presented as a sterile solution for intravenous use. It replaces deficient IgG antibodies and is indicated for patients with primary or secondary immunodeficiency disorders, helping to reduce infection risk.

GNH USA supplies Iqymune as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides cold‑chain logistics to ensure product integrity. Customers receive comprehensive regulatory support and timely delivery across global markets.

Iqymune is used in immunoglobulin replacement therapy for disorders characterized by deficient antibody production.

- Primary immunodeficiency diseases: restores IgG levels to reduce frequency and severity of infections. - Secondary immunodeficiency: replenishes IgG in patients with acquired immune deficiency, such as after chemotherapy or HIV infection. - Hematologic malignancy‑associated hypogammaglobulinemia: supports immune function in conditions like chronic lymphocytic leukemia.

Intravenous immunoglobulin therapy can be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Headache: mild to moderate pain often occurring during or after infusion. - Fever and chills: transient rise in temperature and shaking sensations. - Nausea or vomiting: gastrointestinal discomfort shortly after administration. - Fatigue: feeling of tiredness that may last several hours. - Arthralgia: joint aches without swelling. - Hypertension: temporary increase in blood pressure during infusion.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical intervention. - Thromboembolic events: blood clots that can affect veins or arteries. - Acute renal dysfunction: sudden decrease in kidney function. - Aseptic meningitis: inflammation of the meninges without infection. - Hemolysis: destruction of red blood cells leading to anemia. - Severe thrombocytopenia: markedly low platelet count increasing bleeding risk.

Before initiating Iqymune therapy, clinicians should consider several precautionary measures to ensure patient safety. - Baseline IgG assessment: determine patient’s immunoglobulin levels prior to treatment. - Infusion rate monitoring: start with a slow rate and adjust if reactions occur. - Renal function evaluation: assess kidney status, especially in patients with pre‑existing impairment. - History of IgA deficiency: avoid use in individuals with anti‑IgA antibodies due to risk of anaphylaxis. - Concomitant anticoagulant use: monitor coagulation parameters when patients receive blood thinners. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Iqymune may interact with other medicines, influencing efficacy or safety.

Major Interactions (Avoid): - Live attenuated vaccines: concurrent use can result in inadequate vaccine response or infection. - High‑dose aspirin or NSAIDs: increase risk of renal impairment when combined with IVIG. - Concomitant anticoagulants: may potentiate bleeding tendencies due to platelet dysfunction.

Moderate Interactions (Monitor Closely): - Corticosteroids: may alter immune response, requiring dose adjustments. - Cytotoxic chemotherapy agents: combined immunosuppression can heighten infection risk. - Diuretics: may exacerbate renal stress during infusion. - ACE inhibitors: monitor blood pressure and renal function. - Immunosuppressive biologics: assess for additive immunomodulatory effects.